Regulatable CAR-T cells for safer cancer treatment
SaefCAR: Regulatable CAR-T cells for safe and effective immunotherapy
This study is testing a new kind of CAR-T cell therapy that can be safely controlled in the body, aiming to provide a better and safer treatment option for people with different types of cancer, especially solid tumors.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mabswitch, INC. NIH-funded |
| Lab location | 1 site (Van Nuys, United States) |
| Project ID | NIH-10759600 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of CAR-T cell therapy that can be regulated in vivo, aiming to improve safety and effectiveness for treating various cancers, especially solid tumors. The approach seeks to address significant issues with current CAR-T therapies, such as severe side effects and loss of effectiveness, by creating a system that allows for rapid and reversible control of T cell activation. Patients may benefit from a more tailored and safer immunotherapy option that minimizes the risk of adverse events while maximizing therapeutic potential.
Who could benefit from this research
Good fit: Ideal candidates for this research would include patients with hematological cancers or solid tumors who are seeking innovative treatment options.
Not a fit: Patients with cancers that do not express the targeted antigens or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a safer and more effective immunotherapy option for treating cancers.
How similar studies have performed: While CAR-T cell therapies have shown success in treating certain hematological cancers, this specific approach of regulatable CAR-T cells is novel and has not been extensively tested.
Where this research is happening
Van Nuys, United States
- Mabswitch, INC. — Van Nuys, United States (Active)
Researchers
- Principal investigator: Onakunle, Yemi — Mabswitch, INC.
- Study coordinator: Onakunle, Yemi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.